The Co-Sponsor in the conduct of a Clinical Trial in Germany
International Journal of Drug Regulatory Affairs · 15.09.2024 · 12 (3) · 1-4
DOI: 10.22270/ijdra.v12i3.666 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Regulatory Affairs, online erschienen am 15.09.2024. Verfasst von Raees Ahmed und 2 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
The sponsor is highly relevant in the conduct of clinical trials, both from a financial point of view and in terms of responsibility for study management. Until now, only one sponsor was designated as the primary contact for the conduct of clinical trials. The new regulation (EU) No 536/2014 allows the use of multiple sponsors, so-called co-sponsors. But this also raises new problems and questions for existing contracts and new contracts between sponsors, especially regarding the liability of one or more co-sponsors in the external as well as the internal relationship. This article highlights the issues arising from this amendment and clarifies the differences between a sponsor and a co-sponsor.
Zitieren
APA
Ahmed, R., Süngü, S., & Gerst, C. (2024). The Co-Sponsor in the conduct of a Clinical Trial in Germany. International Journal of Drug Regulatory Affairs, 12(3), 1-4. https://doi.org/10.22270/ijdra.v12i3.666
Vancouver
Ahmed R, Süngü S, Gerst C. The Co-Sponsor in the conduct of a Clinical Trial in Germany. International Journal of Drug Regulatory Affairs. 2024;12(3):1-4. doi:10.22270/ijdra.v12i3.666
BibTeX
@article{Ahmed2024,
author = {Ahmed, Raees and Süngü, Simge and Gerst, Christoph},
title = {The Co-Sponsor in the conduct of a Clinical Trial in Germany},
journal = {International Journal of Drug Regulatory Affairs},
year = {2024},
volume = {12},
number = {3},
pages = {1--4},
doi = {10.22270/ijdra.v12i3.666}
}
EUVIMED